Medacta Group SA (MEDGF)
83.91
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Medacta Group Enterprise Value: 1.827B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 1.827B |
| May 15, 2024 | 1.827B |
| May 14, 2024 | 1.827B |
| May 13, 2024 | 1.827B |
| May 10, 2024 | 1.827B |
| May 09, 2024 | 1.827B |
| May 08, 2024 | 1.827B |
| May 07, 2024 | 1.827B |
| May 06, 2024 | 1.827B |
| May 03, 2024 | 1.827B |
| May 02, 2024 | 1.827B |
| May 01, 2024 | 1.827B |
| April 30, 2024 | 1.827B |
| April 29, 2024 | 1.827B |
| April 26, 2024 | 1.827B |
| April 25, 2024 | 1.827B |
| April 24, 2024 | 1.827B |
| April 23, 2024 | 1.827B |
| April 22, 2024 | 1.827B |
| April 19, 2024 | 1.827B |
| April 18, 2024 | 1.827B |
| April 17, 2024 | 1.827B |
| April 16, 2024 | 1.827B |
| April 15, 2024 | 1.827B |
| April 12, 2024 | 1.827B |
| Date | Value |
|---|---|
| April 11, 2024 | 1.827B |
| April 10, 2024 | 1.827B |
| April 09, 2024 | 1.827B |
| April 08, 2024 | 1.827B |
| April 05, 2024 | 1.827B |
| April 04, 2024 | 1.827B |
| April 03, 2024 | 1.827B |
| April 02, 2024 | 1.827B |
| April 01, 2024 | 1.827B |
| March 28, 2024 | 1.827B |
| March 27, 2024 | 1.827B |
| March 26, 2024 | 1.827B |
| March 25, 2024 | 1.827B |
| March 22, 2024 | 1.827B |
| March 21, 2024 | 1.827B |
| March 20, 2024 | 1.827B |
| March 19, 2024 | 1.827B |
| March 18, 2024 | 1.827B |
| March 15, 2024 | 1.827B |
| March 14, 2024 | 1.827B |
| March 13, 2024 | 1.827B |
| March 12, 2024 | 1.827B |
| March 11, 2024 | 1.827B |
| March 08, 2024 | 1.827B |
| March 07, 2024 | 1.827B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
837.74M
Minimum
May 29 2019
2.822B
Maximum
Nov 23 2021
1.816B
Average
1.793B
Median
Jan 03 2023
Enterprise Value Benchmarks
| AC Immune SA | 221.07M |
| CRISPR Therapeutics AG | 2.619B |
| Addex Therapeutics Ltd | 4.792M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -95.36M |
Enterprise Value Related Metrics
| Earnings Yield | 3.07% |
| Operating Earnings Yield | 4.81% |
| Normalized Earnings Yield | 3.065 |